RAMM Pharma

RAMM Pharma EBIT Growth

The Year-over-Year EBIT Growth of RAMM Pharma (RAMM.CN) as of Oct 24, 2026 is 36.37 %. In the previous year, Year-over-Year EBIT Growth was 4.57 % — a change of 696.72% (higher).

EBIT Growth

36.37 %

YoY

696.72%

Last updated:

Year-over-Year EBIT Growth of RAMM Pharma is 2025 36.37 % . Year-over-Year EBIT Growth of RAMM Pharma was 2024 4.57 % . It decreases by 696.72% higher compared to the previous year.

The RAMM Pharma EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
-1,761.18 CAD
Jan 1, 2020
-37.06 CAD
Jan 1, 2021
12.32 CAD
Jan 1, 2022
-19.34 CAD
Jan 1, 2023
10.84 CAD
Jan 1, 2024
4.57 CAD
Jan 1, 2025
36.37 CAD
The RAMM Pharma EBIT Growth history
YEAREBIT GrowthYoY
36.37 %+696.72%
4.57 %-57.86%
10.84 %-156.01%
-19.34 %-256.95%
12.32 %-133.26%
-37.06 %-97.90%
-1,761.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

Year-over-Year EBIT Growth of RAMM Pharma is 36.37 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's RAMM Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — RAMM Pharma

All Key Metrics — RAMM Pharma